Welcome to our dedicated page for Cingulate SEC filings (Ticker: CING), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cingulate Inc. (CING) SEC filings page on Stock Titan provides organized access to the company’s public disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Capital Market–listed biopharmaceutical company, Cingulate uses its SEC reports to describe progress of its Precision Timed Release™ (PTR™) platform, regulatory milestones for its lead ADHD candidate CTx-1301, and key financing and governance events.
Here you can review Form 8-K current reports that detail material events such as FDA acceptance of the New Drug Application for CTx-1301 with a May 31, 2026 PDUFA target action date, commercial supply agreements with Bend Bio Sciences, purchase agreements with Lincoln Park Capital, and promissory note financings with Avondale Capital. 8-K filings also summarize quarterly earnings press releases, special stockholder meeting results, and executive or board-level changes.
When available, annual reports on Form 10-K and quarterly reports on Form 10-Q provide broader discussion of Cingulate’s business, PTR technology, risk factors, and financial statements. These filings are particularly relevant for understanding the company’s clinical-stage status, R&D spending on CTx-1301 and other candidates in anxiety and neuropsychiatric indications, and its capital structure.
Investors interested in ownership and compensation matters can also monitor proxy statements and, where applicable, Form 4 insider transaction reports to see how directors and officers transact in CING securities. Stock Titan’s platform enhances these documents with AI-powered summaries that explain complex sections, highlight key terms in financing agreements, and surface important dates such as NDA submissions and PDUFA deadlines. Real-time updates from EDGAR ensure that new Cingulate filings, from 8-Ks to periodic reports, appear promptly with plain-language explanations to support deeper analysis of CING’s regulatory and financial disclosures.
Cingulate Inc. (CING) reported an insider equity grant. On 09/30/2025, EVP and CSO Raul Silva received a stock option covering 7,334 shares of common stock at an exercise price of $3.92, expiring 09/30/2035. The filing lists transaction code “A,” indicating an award. The option was granted pursuant to Dr. Silva’s Employment Agreement, as amended, and is held directly. Following the grant, 7,334 derivative securities were beneficially owned.
Cingulate Inc. (CING) reported a Form 4 showing its Chief Commercial Officer received a stock option grant to purchase 30,000 shares at an exercise price of $3.8 on 11/03/2025.
The option expires on 11/03/2035 and vests 25% on the one-year anniversary of the grant date, with the remaining shares vesting in substantially equal monthly installments over the following 36 months. Following the grant, 30,000 derivative securities were beneficially owned, held directly.
Cingulate Inc. (CING) disclosed an initial beneficial ownership report on Form 3 for Bryan Downey, its Chief Commercial Officer. The event date is 11/03/2025. The filing states that no securities are beneficially owned by the reporting person at the time of this report. The form was filed by one reporting person and includes an Exhibit 24 power of attorney.
Cingulate Inc. (CING) entered a financing on November 7, 2025, issuing an unsecured promissory note to Avondale Capital for a $6,570,000 principal amount that carries a 9% annual interest rate and matures in 18 months. The note was sold at a $540,000 original issue discount, generating $6,000,000 in cash proceeds for working capital and general corporate purposes.
Beginning May 7, 2026, the lender may redeem portions of the note up to $660,000 per month. The company may defer up to two redemptions for 30 days each before receiving an FDA “complete response letter,” with each deferral increasing the outstanding balance by 1%. If the note remains outstanding 90 days after its effective date, a monitoring fee applies per a formula tied to the then-outstanding balance.
Subsidiaries provided guarantees. The agreement includes customary defaults; certain defaults permit increases to the outstanding balance by 15% (Major Trigger) or 5% (Minor Trigger), each up to three times, and default interest up to 22% per year. Covenants restrict variable-rate transactions, include a most-favored-nation feature on future debt, allow prepayment, and give the lender an option (with company consent) to reinvest up to $5,000,000 on the same terms.
Cingulate Inc. announced a regulatory milestone: the FDA has accepted for review the New Drug Application for CTx-1301 (dexmethylphenidate), the company’s lead candidate for treating ADHD in children and adults. The FDA assigned a PDUFA target action date of May 31, 2026, setting the timeline for a decision after the agency’s standard review process. This step moves CTx-1301 into formal evaluation but does not indicate approval.
Cingulate Inc. reported the results of a Special Meeting of Stockholders held on September 25, 2025. Stockholders approved, for purposes of complying with Nasdaq Listing Rule 5635(d), the potential issuance of more than 20% of the company’s issued and outstanding common stock under a purchase agreement with Lincoln Park Capital Fund, LLC. This approval gives the company the stockholder authorization it needs to use that agreement for future share issuances.
For this Issuance Proposal, 1,597,394 shares were voted in favor, 213,885 against, and 9,561 abstained. Stockholders also approved a proposal to adjourn the Special Meeting if additional time were needed to secure votes on the Issuance Proposal, with 1,795,696 shares for, 125,763 against, and 19,805 abstentions, though adjournment was ultimately not required.